Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Minghui’s MHB088C will soon start phase 3 in China.
The conjugates SYS6005 and TQB2101 feature among first-in-human study entrants.
Imfinzi hits on disease-free survival, but BCG won't be displaced.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
